Journal Article

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes

Bouillet, Benjamin, Denimal, Damien, Passilly-Degrace, Patricia, Rouland, Alexia, Bataille, Amandine, Simoneau, Isabelle, Bergas, Victoria, Duvillard, Laurence, Pais-de-Barros, Jean-Paul, Demizieux, Laurent, Petit, Jean-Michel, Vergès, Bruno

2023

Overview

Background Emerging evidence supports that dihydroceramides (DhCer) and ceramides (Cer) contribute to the pathophysiology of insulin resistance and liver steatosis, and that their circulating concentrations are independently associated with cardiovascular outcomes. Circulating DhCer levels are increased in patients with type 2 diabetes (T2D). On the other hand, the GLP-1 receptor agonist liraglutide reduces major adverse cardiac events, insulin resistance and liver steatosis in T2D patients. The main purpose of the present study was therefore to investigate whether liraglutide decreases circulating levels of DhCer and Cer in T2D patients, which could be a mechanism involved in its cardiometabolic benefits. The secondary purpose was to assess the relationship between liraglutide-induced changes in DhCer/Cer levels and insulin resistance and liver steatosis. Methods Plasma concentrations of 11 DhCer and 15 Cer species were measured by a highly-sensitive mass spectrometry system in 35 controls and 86 T2D patients before and after 6 months of liraglutide (1.2 mg/day). Insulin resistance was estimated by the triglyceride-glucose (TyG) index. Liver fat content (LFC) was assessed in 53 patients by proton magnetic resonance spectroscopy. Results Plasma levels of total DhCer, 7 DhCer and 7 Cer species were increased in T2D patients compared to controls. Liraglutide decreased total DhCer by 15.1% (p = 0.005), affecting 16:0 (p = 0.037), 18:0 (p < 0.0001), 18:1 (p = 0.0005), 20:0 (p = 0.0003), 23:0 (p = 0.005) and 24:1 (p = 0.04) species. Total plasma Cer did not significantly change after liraglutide (p = 0.18), but 5 Cer species decreased significantly, i.e. 18:0 and 18:1 (both p < 0.0001), 19:0 and 24:1 (both p < 0.01) and 26:1 (p = 0.04). In multivariate analysis, the reduction in DhCer after liraglutide was independently associated with the reduction in LFC (p = 0.0005) and in TyG index (p = 0.05). Conclusions Liraglutide reduces plasma levels of numerous DhCer and Cer species in T2D patients, which may contribute to the cardiovascular benefit observed in the LEADER trial. The independent association between the decrease in plasma DhCer level with the reduction in LFC and TyG index adds new insights regarding the relationship between DhCer, liver steatosis and insulin resistance. Trial registration ClinicalTrials.gov identifier: NCT02721888.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Angiology / Antidiabetics / Cardiology / Cardiovascular disease / Ceramides / Chromatography / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - diagnosis / Diabetes Mellitus, Type 2 - drug therapy / Dihydroceramides / Fatty Liver / GLP-1 receptor agonists / High density lipoprotein / Humans / Hypoglycemic Agents - adverse effects / Insulin Resistance / Lipids / Liraglutide / Liraglutide - adverse effects / Liver / Magnetic resonance spectroscopy / Mass spectroscopy / Medicine / Medicine & Public Health / Metabolism / Multivariate analysis / Normal distribution / Novel Cardioprotective Antidiabetic Medications / Pathophysiology / Plasma / Plasma levels / Species / Steatosis / Triglycerides / Type 2 diabetes